NCT06222268View on ClinicalTrials.gov

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
PTSDPost Traumatic Stress Disorder
Interventions
DRUG

Cannabidiol (CBD) only

Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.

DRUG

Placebo only

Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD

DRUG

Delta-9-tetrahydrocannabinol (THC) only

Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.

DRUG

THC:CBD 1:1

Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.

DRUG

THC:CBD 1:10

Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.

Trial Locations (3)

48201

Tolan Park Medical Building, Detroit

Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences, Detroit

WSU MR Research Facility DMC Harper University Hospital, Detroit

All Listed Sponsors
lead

Wayne State University

OTHER